Anesthesia regimen linked to post-orthognathic op pain

Anesthesia regimen linked to post-orthognathic op pain
Patients undergoing orthognathic maxillofacial surgery experience more pain postoperatively if they receive anesthesia with propofol and remifentanil versus inhalational agents and longer-acting opioids, according to a study published in the Summer 2012 issue of Anesthesia Progress.

(HealthDay) -- Patients undergoing orthognathic maxillofacial surgery experience more pain postoperatively if they receive anesthesia with propofol and remifentanil versus inhalational agents and longer-acting opioids, according to a study published in the Summer 2012 issue of Anesthesia Progress.

Soudeh Chegini, from the Wexham Park Hospital in Slough, U.K., and colleagues retrospectively compared the recovery characteristics of 51 patients who had undergone orthognathic maxillofacial surgery. Twenty-one had received anesthesia with intravenous propofol and remifentanil and 30 had received anesthesia with volatile inhalational agents and longer-acting opioids.

The researchers found that patients who had received propofol and remifentanil reported significantly higher in the first four hours after surgery. The median for this group was shorter (65 versus 93 minutes), though this did not reach . Both groups had similar early postoperative opioid usage, hemodynamic parameters, and postoperative nausea and vomiting.

"We believe this is the first report comparing the effects of different opioid-based anesthetic regimens on early recovery from orthognathic surgery, and we believe this report may be used as the starting point for a controlled study," Chegini and colleagues conclude.

More information: Abstract
Full Text

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

British Lords hold ten-hour debate on assisted dying

Jul 19, 2014

Members of Britain's unelected House of Lords spent almost ten hours on Friday discussing whether to legalise assisted dying, in an often emotional debate putting the question back on the agenda, if not on the statute books.

AbbVie, Shire agree on $55B combination

Jul 18, 2014

The drugmaker AbbVie has reached a deal worth roughly $55 billion to combine with British counterpart Shire and become the latest U.S. company to seek an overseas haven from tax rates back home.

Safety problems at US germ labs acknowledged

Jul 16, 2014

(AP)—The director of the U.S. Centers for Disease Control and Prevention acknowledged Wednesday that systemic safety problems have for years plagued federal public health laboratories that handle dangerous ...

User comments